Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,454,749
  • Shares Outstanding, K 55,419
  • Annual Sales, $ 0 K
  • Annual Income, $ -155,130 K
  • 60-Month Beta 1.96
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.84
  • Number of Estimates 3
  • High Estimate -0.78
  • Low Estimate -0.93
  • Prior Year -0.75
  • Growth Rate Est. (year over year) -12.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.18 +115.52%
on 12/20/19
43.56 -39.74%
on 12/23/19
+13.41 (+104.44%)
since 12/17/19
3-Month
8.11 +223.67%
on 10/21/19
43.56 -39.74%
on 12/23/19
+17.75 (+208.82%)
since 10/17/19
52-Week
6.75 +288.89%
on 10/01/19
43.56 -39.74%
on 12/23/19
+13.64 (+108.17%)
since 01/17/19

Most Recent Stories

More News
Intra-Cellular Therapies Prices Public Offering of Common Stock

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock...

ITCI : 26.25 (-1.43%)
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of 10,000,000 shares of its common stock. In connection...

JPM : 138.20 (+0.69%)
ITCI : 26.25 (-1.43%)
Intra-Cellular Therapies to Present at the 38th Annual J.P. Morgan Healthcare Conference

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D.,...

JPM : 138.20 (+0.69%)
ITCI : 26.25 (-1.43%)
Moving Average Crossover Alert: Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. (ITCI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

ITCI : 26.25 (-1.43%)
ITCI Crosses Above Average Analyst Target

In recent trading, shares of Intra-Cellular Therapies Inc have crossed above the average analyst 12-month target price of $23.00, changing hands for $36.51/share. When a stock reaches the target an analyst...

ITCI : 26.25 (-1.43%)
Company News For Dec 24, 2019

Companies in the news are: ACB, APA, ITCI, SRPT

SRPT : 127.90 (-1.84%)
ITCI : 26.25 (-1.43%)
APA : 32.67 (-1.30%)
ACB : 2.13 (-0.93%)
Look for Shares of Intra-Cellular T to Potentially Pullback after Yesterday's 173.15% Rise

Intra-Cellular T (NASDAQ:ITCI) traded in a range yesterday that spanned from a low of $23.75 to a high of $34.43. Yesterday, the shares gained 173.2%, which took the trading range above the 3-day high...

ITCI : 26.25 (-1.43%)
FDA Approves Intra-Cellular Therapies' Novel Antipsychotic, CAPLYTA(R) (lumateperone) for the Treatment of Schizophrenia in Adults

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA (lumateperone)...

ITCI : 26.25 (-1.43%)
Is the Options Market Predicting a Spike in Intra-Cellular Therapies (ITCI) Stock?

Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

ITCI : 26.25 (-1.43%)
45.0% Return Seen to Date on SmarTrend Intra-Cellular T Call (ITCI)

SmarTrend identified an Uptrend for Intra-Cellular T (NASDAQ:ITCI) on October 29th, 2019 at $8.92. In approximately 2 months, Intra-Cellular T has returned 44.96% as of today's recent price of $12.93....

ITCI : 26.25 (-1.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ITCI with:

Business Summary

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular...

See More

Key Turning Points

2nd Resistance Point 27.50
1st Resistance Point 26.88
Last Price 26.25
1st Support Level 25.89
2nd Support Level 25.52

See More

52-Week High 43.56
Fibonacci 61.8% 29.50
Last Price 26.25
Fibonacci 50% 25.16
Fibonacci 38.2% 20.81
52-Week Low 6.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar